title: Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.
abstract: Hemophilic bleeding into joints causes synovial and microvascular proliferation and inflammation (hemophilic synovitis) that contribute to end-stage joint degeneration (hemophilic arthropathy), the major morbidity of hemophilia. New therapies are needed for joint deterioration that progresses despite standard intravenous (IV) clotting factor replacement. To test whether factor IX within the joint space can protect joints from hemophilic synovitis, we established a hemophilia B mouse model of synovitis. Factor IX knockout (FIX(-/-)) mice received a puncture of the knee joint capsule with a needle to induce hemarthrosis; human factor IX (hFIX) was either injected through the needle into the joint space (intraarticularly) or immediately delivered IV. FIX(-/-) mice receiving intraarticular FIX protein were protected from synovitis compared with mice receiving same or greater doses of hFIX IV. Next, adeno-associated virus (AAV) gene transfer vectors expressing hFIX were injected into knee joints of FIX(-/-) mice. Joints treated with 10(10) vector genomes (vg)/joint AAV2-, AAV5-, or AAV8-hFIX or 2.5 x 10(9) vg/joint AAV5-hFIX developed significantly fewer pathologic changes 2 weeks after injury compared with the pathology of control injured contralateral hind limbs. Extravascular factor activity and joint-directed gene transfer may ameliorate hemophilic joint destruction, even in the absence of circulating FIX.
authors: Gene Therapy Center, School of Medicine, University of North Carolina at Chapel Hill, NC 27599-7220, USA.
authors: Junjiang
authors: J
authors: Sun
authors: Narine
authors: N
authors: Hakobyan
authors: Leonard A
authors: LA
authors: Valentino
authors: Brian L
authors: BL
authors: Feldman
authors: R Jude
authors: RJ
authors: Samulski
authors: Paul E
authors: PE
authors: Monahan
mesh_terms: D000818:Animals; D001682:Biological Availability; D000229:Dependovirus / Q000235:genetics; D004195:Disease Models, Animal; D005164:Factor IX / Q000008:administration & dosage* / Q000235:genetics* / Q000493:pharmacokinetics; D015316:Genetic Therapy; D005822:Genetic Vectors; D002836:Hemophilia B / Q000097:blood / Q000150:complications / Q000473:pathology / Q000628:therapy*; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D007270:Injections, Intra-Articular; D007275:Injections, Intravenous; D007592:Joint Diseases / Q000209:etiology / Q000517:prevention & control; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D013585:Synovitis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D005164:Factor IX